Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 May 25

PMID 38792328

Authors

Dario Cocito

Erdita Peci

Maria Claudia Torrieri

Marinella Clerico

Affiliations

Soon will be listed here.

Abstract

: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease. Neuropathic pain (NP), related to peripheral inflammation, is among its earliest manifestations. This preliminary open-label investigation aimed to evaluate the efficacy of ultramicronized Palmitoylethanolamide (umPEA) in the management of NP. : A total of 14 patients with CIDP, already undergoing immunoglobulin (Ig) therapy, were divided into two groups: Group A received umPEA 600 mg twice daily in addition to Ig for 60 days, followed by Ig alone until the end of the observation (180 days); Group B received Ig alone for 120 days and subsequently umPEA + Ig in the last 60 days of the study. Painful symptom intensity and quality of life were assessed by the Numeric Rating Scale, Neuropathic Pain Symptoms Inventory, and Five Dimensions Health Questionnaire. The safety umPEA profile was evaluated. : UmPEA in addition to immunoglobulins allowed for a significant improvement over time in all NP symptoms intensity ( = 0.0007) and in patients' quality of life ( = 0.0036). : This study suggests umPEA as a safe and effective treatment in addition to immunoglobulins to improve NP, ameliorating the patient's health status. These results highlight the importance of neuroinflammation modulation in the management of CIDP's painful symptoms, drawing attention to umPEA's potential use also in neuropathies of different etiologies.

Citing Articles

Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an In Vitro Model.

Galla R, Mule S, Ferrari S, Grigolon C, Molinari C, Uberti F Int J Mol Sci. 2024; 25(16).

PMID: 39201765 PMC: 11354262. DOI: 10.3390/ijms25169079.

References

Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato A . Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012; 13(9):1121-30. DOI: 10.1111/j.1526-4637.2012.01432.x. View

Petrosino S, Cordaro M, Verde R, Moriello A, Marcolongo G, Schievano C . Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front Pharmacol. 2018; 9:249. PMC: 5870042. DOI: 10.3389/fphar.2018.00249. View

Loverme J, La Rana G, Russo R, Calignano A, Piomelli D . The search for the palmitoylethanolamide receptor. Life Sci. 2005; 77(14):1685-98. DOI: 10.1016/j.lfs.2005.05.012. View

Cruccu G, Stefano G, Marchettini P, Truini A . Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain - Sciatica. CNS Neurol Disord Drug Targets. 2019; 18(6):491-495. PMC: 7132032. DOI: 10.2174/1871527318666190703110036. View

Lillie E, Patay B, Diamant J, Issell B, Topol E, Schork N . The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Per Med. 2011; 8(2):161-173. PMC: 3118090. DOI: 10.2217/pme.11.7. View

Zhao H, Alam A, Chen Q, A Eusman M, Pal A, Eguchi S . The role of microglia in the pathobiology of neuropathic pain development: what do we know?. Br J Anaesth. 2017; 118(4):504-516. DOI: 10.1093/bja/aex006. View

Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E . Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014; 11:136. PMC: 4171547. DOI: 10.1186/s12974-014-0136-0. View

Skaper S, Facci L, Fusco M, Della Valle M, Zusso M, Costa B . Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2013; 22(2):79-94. DOI: 10.1007/s10787-013-0191-7. View

Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G . The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008; 139(3):541-550. DOI: 10.1016/j.pain.2008.06.003. View

10.

Shah S, Chandrashekar H, Manji H, Davagnanam I . Cranial nerve, spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Pract Neurol. 2012; 12(1):68-9. DOI: 10.1136/practneurol-2011-000040. View

11.

Lehmann H, Burke D, Kuwabara S . Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019; 90(9):981-987. DOI: 10.1136/jnnp-2019-320314. View

12.

Esposito E, Cuzzocrea S . Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targets. 2013; 12(1):55-61. DOI: 10.2174/1871527311312010010. View

13.

Clayton P, Hill M, Bogoda N, Subah S, Venkatesh R . Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci. 2021; 22(10). PMC: 8157570. DOI: 10.3390/ijms22105305. View

14.

Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B . Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets. 2013; 12(1):34-44. DOI: 10.2174/1871527311312010008. View

15.

Evangelista M, Cilli , De Vitis R, Militerno A, Fanfani F . Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study. CNS Neurol Disord Drug Targets. 2018; 17(4):291-298. DOI: 10.2174/1871527317666180420143830. View

16.

Haefeli M, Elfering A . Pain assessment. Eur Spine J. 2005; 15 Suppl 1:S17-24. PMC: 3454549. DOI: 10.1007/s00586-005-1044-x. View

17.

Petrosino S, Di Marzo V . The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2016; 174(11):1349-1365. PMC: 5429331. DOI: 10.1111/bph.13580. View

18.

Girach A, Julian T, Varrassi G, Paladini A, Vadalouka A, Zis P . Quality of Life in Painful Peripheral Neuropathies: A Systematic Review. Pain Res Manag. 2019; 2019:2091960. PMC: 6556282. DOI: 10.1155/2019/2091960. View

19.

Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G . Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Pain Physician. 2016; 19(2):11-24. View

20.

Petrosino S, Moriello A . Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review. Int J Mol Sci. 2020; 21(24). PMC: 7765232. DOI: 10.3390/ijms21249526. View